Get started

Pharmaceuticals

MERCK GOOD OPPORTUNITY Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891 Entry on the bullish break of the dynamic trendine or on exceeding the weekly maximum. Excellent operation with a risk / return ratio of 1.20
NYSE:MRKLong
by UnknownUnicorn25541012
Vertex, a great pharmaceutical at a discounted priceA company with over 10 years of consistent and constant growth, a wide coverage of products already on the market and... despite an excellent quarterly for a news or a trail .. boom .. It drops suddenly ? In my opinion this is sheer market madness, the sites I use as a reference for fundamental analysis confirm to me what I say, the company always be more than 50% below its fair value. To confirm my conviction is also Market Miracle the algorithmic advisor, which has provided an entry signal on the stock at the price of 188 usd, also providing a valuable indication ... that is, that the price of the stock is in the area of oversold. In the immediate I don’t expect a great climb but given the solidity of the company is definitely a low-risk investment that, given the discounted price can also lead to very interesting gains in the medium term ... obviously if the price starts to rise. So I decided to increase the positions on Vertex Pharmaceuticals $VRTX hoping to be on the side of the market that as you know always has the reason on its side. This idea is based on a signal generated by the advisor Marketmiracle, down on this page you will find the link to the page of signals of the advisor that you can see for free without any cost or registration
NASDAQ:VRTXLong
by MarketMiracleAdvisor
Are we close to observe a breakout on NVAX ?Novavax COVID-19 vaccine more than 90% effective in U.S trial according to Reuters. Despite positive news (which we do not trade), we will share with you our current view on Novavax. a) The price is inside a descending Wedge, and due to positive news, we are observing a bullish GAP, and we may see the price outside the Wedge pattern b) The general strategy we will use to develop bullish setups on the pharmaceutical company is waiting for the price to reach 250 - 270 and then an ABC corrective pattern, as you can see on the chart. c) IF that scenario happens, we will trade above B, and our stop loss will be set below C d) Regarding the targets, we will be using the Fibo Extensions of the major descending wedge Thanks for reading!
NASDAQ:NVAXLong
by ThinkingAntsOk
5
PIRS - To the $4 💰-The company said that it has reached into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris’ proprietary Anticalin® technology. -PIRS went on to explain that the collaboration will enable it to combine its robust discovery engine with Genentech’s targets, as well as its preclinical and clinical development expertise. As a result, the two will work together to create novel therapies for the treatment of respiratory and other ophthalmological diseases. -Importantly, these two focus areas of the collaboration are uniquely suited to the advantages offered by the small size of Anticalin proteins when delivered locally. -Under the terms of the agreement, Pieris will receive $20 million as an upfront payment and may be eligible to receive more than $1.4 billion in additional milestone payments across multiple programs, as well as tiered royalties for commercialized programs. -In exchange, PIRS will be responsible for the discovery and early preclinical development of the programs. Genentech will be responsible for IND-enabling activities, clinical development, and commercialization of the programs. Moreover, Genentech will have the option to select additional targets in return for an option exercise fee. -This news is huge! First and foremost, entering into a partnership with a company the size of Genentech comes with several advantages. Not to mention, the funding offered through this partnership will help to bolster Pieris Pharmaceuticals’ balance sheet. -At the same time, none of the internal programs at the company are included in the partnership, meaning that everything that comes out of this collaboration will be a new revenue opportunity.
PLong
by caldooninvestment
12
Is this love, baby, or is it confusion?This is an Elliot Wave projection suggesting we've just completed Wave 2 of a standard 5 Up formation. Wave 2 is often a 0.5 or 0.618 pullback on Wave 1. Wave 3 is often related to Wave 1 by 1:1, 1:1.618, or 1:2.618 (don't ask me why). Wave 4 often pulls back to the .382 of Wave 3. Wave 5 is least reliable and may replicate Wave 1 when Wave 3 extends, or extend to the 1.618 if Wave 3 replicates Wave 1 (again, dont ask me to explain this woo woo theory). Possible Wave 2 targets ($CAD): 8.88, 10, 11.65, 16 Possible Wave 5 targets: 11, 13.37 14.59, 20 The MACD is turning up with a bullish divergence shown in yellow. NOTE This analysis is akin to random guessing and finger painting. These price targets and predictions are in no way intended as finacial advices. If you want to be independently financially, we recommend education as the first and foremost step in your journey.
MLong
by bluedog360
5
Syndax is about to see huge gains to ~$24 a share again. Syndax Pharmaceuticals recently had POSITIVE interim data on their phase 2 study in SNDX-5613 for Leukemia. This data was positive as they saw a 48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved minimal residual disease-negative status. Out of 43 of patients evaluated, 31 were able to be used as for significant data. These two pieces of news are huge as Leukemia is an extremely life threatening disease where more than 50% of people are dead within 5 years. Any drug that can help save these peoples lives is priceless and the upside of this company is definitely there. I believe the sell off was a big Hedge fund taking their profits and exiting as they were not satisfied with the Positive results from the study, causing stop losses and further panic selling. This has also caused an overcorrection in the stock price which should correct once another big player enters and brings the rest of the bulls with them. There is a rough bottom at $13 currently on the stock and it is possible for the stock to go down further as this is simply my opinion and is for educational purposes only.
NASDAQ:SNDXLong
by xLucky900
HEPA - a good buy opportunity? Very likely for me!First of all, I am not an expert when it comes to pharmaceutical companies! Why did I pick Hepion Pharmaceuticals (@hepionpharma)? 1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1) 2. They came from a super high share price and are currently on a super low level 3. They are working on a product CRV431 (recently completed Phase 1 of 3) to tackle chronic liver disease and so far the results seem promising: Half a billion people worldwide are at risk unless new therapies are found. CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. CRV431 meets all of Hepion’s criteria for an effective and unique pleiotropic liver disease drug. Currently Phase 1 consists of three parts and the collective data from the Parts 1 and 2 demonstrate a favorable pharmacological, pharmacokinetic, and safety profile for CRV431. Part 3 data results are expected and with Phase 2 we might see bigger interest. Take a look at the chart and the health of the company with future prospective - then shape your own opinion. - This is no financial advice, so trade with care!- For transparency reasons: I am invested in $HEPA with 2/10 of my stock account size.
NASDAQ:HEPALong
by RedFoxTrading